Loading clinical trials...

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression

NCT03808662•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18 or older
•Willing and able to provide informed consent
•Metastatic disease detected on imaging and histologically confirmed:
•Triple negative breast cancer TNBC (ER \<1%, PR \<1%, her-2-neu 0- 1+ by IHC or FISH-negative or as determined by MD discretion)
•OR NSCLC (without known EGFR mutation or ALK/ROS1 rearrangement)
•OR Other high-risk breast cancer (per physician's discretion) progressed on hormone or systemic therapy, regardless of ER/HER2 status
•OR NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations with disease progression on first-line tyrosine kinase inhibitor
•Note:
•Biopsy of metastasis prior to enrollment is per treating physician's discretion per standard of care. It is preferred but not required.
•These patients are selected for the study given the similar survival outcomes when given standard of care therapies
+38 more criteria

Exclusion Criteria

•Pregnancy.
•Leptomeningeal disease.
•Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma.
•Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.

Locations (10)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Rockville Centre

Rockville Centre, New York, United States

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

Fred Hutchinson Cancer Research Center (Data Analysis Only)

Seattle, Washington, United States

Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only)

Toronto, Ontario, Canada

Key Dates

Start Date

January 16, 2019

Primary Completion Date

January 1, 2027

Completion Date

January 1, 2027

Last Updated

February 4, 2026

Enrollment

107

ACTUAL participants

Conditions

TNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLCNSCLC Stage IVNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNSCLC Stage IV Without EGFR/ALK Mutation

Interventions

Sterotactic Body Radiotherapy/SBRT

RADIATION

Standard of care

DRUG

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITINGPHASE1/PHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Magnetic Resonance Imaging of the Lung: Oncological Applications

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors